Back to top

vaccines: Archive

Zacks Equity Research

Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?

Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.

MRKPositive Net Change BAYRYPositive Net Change MRNAPositive Net Change ALLOPositive Net Change

Zacks Equity Research

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

ALKSPositive Net Change BAYRYPositive Net Change NVAXPositive Net Change SNDXPositive Net Change

Zacks Equity Research

Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others

Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.

BMYNegative Net Change MRKPositive Net Change LLYPositive Net Change GILDNegative Net Change

Zacks Equity Research

GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook

GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.

SNYPositive Net Change GSKPositive Net Change JNJPositive Net Change VIRPositive Net Change

Andrew Rocco

Biggest Earnings Week of the Season: Key Stocks to Watch

This week is undoubtedly the most important week of earnings season. Andrew Rocco highlights key industries to watch including big tech, biotech, and energy.

AMZNPositive Net Change AAPLPositive Net Change AMDPositive Net Change XOMPositive Net Change PFEPositive Net Change NVDAPositive Net Change QQQPositive Net Change GOOGLPositive Net Change SNAPPositive Net Change METAPositive Net Change

Zacks Equity Research

GSK Gears Up to Report Q4 Earnings: What's in the Cards?

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.

GSKPositive Net Change SNDXPositive Net Change RCUSPositive Net Change VIRPositive Net Change

Zacks Equity Research

Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change